tiprankstipranks
Nkarta reports Q2 EPS (34c), consensus (45c)
PremiumThe FlyNkarta reports Q2 EPS (34c), consensus (45c)
3M ago
Nkarta upgraded to Strong Buy from Outperform at Raymond James
Premium
The Fly
Nkarta upgraded to Strong Buy from Outperform at Raymond James
3M ago
Nkarta reports Q2 EPS (34c), consensus (45c)
Premium
The Fly
Nkarta reports Q2 EPS (34c), consensus (45c)
3M ago
Nkarta Advances Clinical Trials and Explores New Treatments
PremiumCompany AnnouncementsNkarta Advances Clinical Trials and Explores New Treatments
5M ago
Nkarta initiates trial of NKX019 in lupus nephritis
Premium
The Fly
Nkarta initiates trial of NKX019 in lupus nephritis
5M ago
Nkarta initiates trial of NKX019 in lupus nephritis
Premium
The Fly
Nkarta initiates trial of NKX019 in lupus nephritis
5M ago
Promising Biopharma Nkarta (NASDAQ:NKTX) Not for the Faint-Hearted
PremiumMarket NewsPromising Biopharma Nkarta (NASDAQ:NKTX) Not for the Faint-Hearted
8M ago
Nkarta price target raised to $16 from $15 at Canaccord
Premium
The Fly
Nkarta price target raised to $16 from $15 at Canaccord
8M ago
Nkarta prices 21M shares at $10.00 in underwritten offering
Premium
The Fly
Nkarta prices 21M shares at $10.00 in underwritten offering
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100